Reliant Pharmaceuticals
In today's world, Reliant Pharmaceuticals is a topic that has gained great relevance and has captured the attention of a large number of people in different contexts and situations. The importance of Reliant Pharmaceuticals has become evident in various fields, from science to politics, culture and society in general. It is a topic that has sparked debate and constant conversation, generating conflicting opinions and promoting reflection on its impact and meaning. In this article, we will delve into the different aspects of Reliant Pharmaceuticals, exploring its different facets and its relevance in the current era.
 | This article needs additional citations for verification. (June 2015) |
| Industry | Pharmaceuticals |
|---|---|
| Defunct | December 2007 |
| Fate | Acquired by GlaxoSmithKline |
Key people | Joseph J. Krivulka (co-founder) |
Reliant Pharmaceuticals was a company purchased by GlaxoSmithKline in December 2007 for $1.65B.[1] Co-founded by Joseph J. Krivulka.
It was known for six major products, including Lovaza (Omega-3), Axid (H2 blocker), Dynacirc CR (calcium channel blocker), Antara (fenofibrate), InnoPran XL (beta blocker), Lescol XL (Fluvastatin), and Rythmol SR (Class IC anti-arrhythmic).
Reliant Pharmaceuticals, Inc. was a pharmaceutical company that specialized in the development, commercialization and marketing of prescription therapeutic products. Reliant marketed six cardiovascular products in the United States and focused on promoting its products to targeted primary care and specialty physicians, as well as selected hospitals and academic centers in the United States. Reliants' sales force consisted of approximately 650 sales and marketing professionals nationwide.
In 2007, Reliant Pharmaceuticals was acquired by GSK for $1.65 billion in cash, after Reliant recorded net sales of $341 million in the nine months leading to September 30, 2007.[2] The Lovaza drug accounted for 60% of the sales of the company for that period.[3]
References
- ^ Reliant Redirect – GlaxoSmithKline
- ^ "GSK to Acquire Reliant Pharmaceuticals for $1.65B". GEN - Genetic Engineering and Biotechnology News. 2007-11-21. Retrieved 2019-10-21.
- ^ Van Arnum, Patricia (2007-11-29). "GlaxoSmithKline to Acquire Reliant Pharmaceuticals for $1.65 Billion". PharmaTech. Retrieved 2019-10-21.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |